Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Adriano Salaroli"'
Publikováno v:
European Journal of Case Reports in Internal Medicine (2023)
Myomatous erythrocytosis syndrome (MES) is a rare gynaecological condition associated with the presence of a uterine fibroid and isolated polycythaemia. The main characteristic of MES is that haemoglobin returns to a normal level after removal of the
Externí odkaz:
https://doaj.org/article/f63bff31e1af4305b720fb386476fe31
Publikováno v:
European Journal of Case Reports in Internal Medicine (2021)
We report the case of a 76-year-old man presenting with reactive haemophagocytic lymphohistiocytosis (rHLH) in the setting of disseminated prostate cancer. This often fatal syndrome must be diagnosed early in order to maximize survival. Treatment sho
Externí odkaz:
https://doaj.org/article/c5f0d15c9df446f094dc1f89e3bc6a61
Autor:
Massimo Breccia, Adriano Salaroli, Giuseppina Loglisci, Paola Finsinger, Alessandra Serrao, Giuliana Alimena
Publikováno v:
Haematologica, Vol 97, Iss 2 (2012)
Externí odkaz:
https://doaj.org/article/6a134ab9a19f4f3a97c1f0134dbe013c
Autor:
Massimo Breccia, Giuseppina Loglisci, Paola Finsinger, Adriano Salaroli, Alessandra Serrao, Giuliana Alimena
Publikováno v:
Haematologica, Vol 96, Iss 12 (2011)
Externí odkaz:
https://doaj.org/article/e65b35419def41eb945fce09be84c7ea
Autor:
Massimo Breccia, Vincenzo Federico, Giuseppina Loglisci, Adriano Salaroli, Alessandra Serrao, Giuliana Alimena
Publikováno v:
Haematologica, Vol 96, Iss 10 (2011)
Externí odkaz:
https://doaj.org/article/dcdb8fc0295b4f44a2ceea1a3673bbcf
Autor:
Massimo Breccia, Corrado Girmenia, Roberto Latagliata, Giuseppina Loglisci, Michelina Santopietro, Vincenzo Federico, Luigi Petrucci, Alessandra Serrao, Adriano Salaroli, Giuliana Alimena
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 3, Iss 1, Pp e2011021-e2011021 (2011)
Background: Imatinib has become first line therapy in chronic myeloid leukemia patients. Little is known about the infective consequences during the treatment with this drug in large series of chronic phase patients. Material and methods: From Januar
Externí odkaz:
https://doaj.org/article/9d519acc51fc4e598bebc214ede8b9fa
Autor:
Michelina Santopietro, Giuseppina Loglisci, Roberto Latagliata, Corrado Girmenia, Massimo Breccia, Vincenzo Federico, Luigi Petrucci, Alessandra Serrao, Adriano Salaroli, Giuliana Alimena
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 3, Iss 1, Pp e2011021-e2011021 (2011)
Background: Imatinib has become first line therapy in chronic myeloid leukemia patients. Little is known about the infective consequences during the treatment with this drug in large series of chronic phase patients. Material and methods: From Januar
Externí odkaz:
https://doaj.org/article/9a90d56bf7c5498a9db1d9f61dc2fc14
Publikováno v:
European Journal of Case Reports in Internal Medicine.
Myomatous erythrocytosis syndrome (MES) is a rare gynaecological condition associated with the presence of a uterine fibroid and isolated polycythaemia. The main characteristic of MES is that haemoglobin returns to a normal level after removal of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbefd923827755a2b9a0cabdc484c298
https://doi.org/10.12890/2023_003722
https://doi.org/10.12890/2023_003722
Publikováno v:
Current Opinion in Oncology. 32:434-441
Purpose of review Chimeric antigen receptor (CAR) T-cell therapy is an innovative form of adoptive cellular immunotherapy targeting CD19 in its most advanced form. Up to 30% of infused patients achieve long-term survival, meaning that 70% of patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::695bd4b03d9d781cb4cf4260a994929c
https://doi.org/10.1097/cco.0000000000000671
https://doi.org/10.1097/cco.0000000000000671
Autor:
Fabio Andreozzi, Fulvio Massaro, Sebastian Wittnebel, Chloé Spilleboudt, Philippe Lewalle, Adriano Salaroli
Publikováno v:
International journal of molecular sciences. 23(7)
For decades, intensive chemotherapy (IC) has been considered the best therapeutic option for treating acute myeloid leukemia (AML), with no curative option available for patients who are not eligible for IC or who have had failed IC. Over the last fe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23545c39c09819dfff2e4d08460b7442
https://pubmed.ncbi.nlm.nih.gov/35409248
https://pubmed.ncbi.nlm.nih.gov/35409248